176 related articles for article (PubMed ID: 31066943)
1. Deferiprone exerts a dose-dependent reduction of liver iron in adults with iron overload.
Binding A; Ward R; Tomlinson G; Kuo KHM
Eur J Haematol; 2019 Aug; 103(2):80-87. PubMed ID: 31066943
[TBL] [Abstract][Full Text] [Related]
2. Deferiprone as an oral iron chelator in sickle cell disease.
Voskaridou E; Douskou M; Terpos E; Stamoulakatou A; Meletis J; Ourailidis A; Papassotiriou I; Loukopoulos D
Ann Hematol; 2005 Jul; 84(7):434-40. PubMed ID: 15809885
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
Maggio A; Kattamis A; Felisi M; Reggiardo G; El-Beshlawy A; Bejaoui M; Sherief L; Christou S; Cosmi C; Della Pasqua O; Del Vecchio GC; Filosa A; Cuccia L; Hassab H; Kreka M; Origa R; Putti MC; Spino M; Telfer P; Tempesta B; Vitrano A; Tsang YC; Zaka A; Tricta F; Bonifazi D; Ceci A
Lancet Haematol; 2020 Jun; 7(6):e469-e478. PubMed ID: 32470438
[TBL] [Abstract][Full Text] [Related]
4. Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.
Viprakasit V; Nuchprayoon I; Chuansumrit A; Torcharus K; Pongtanakul B; Laothamatas J; Srichairatanakool S; Pooliam J; Supajitkasem S; Suriyaphol P; Tanphaichitr VS; Tuchinda S
Am J Hematol; 2013 Apr; 88(4):251-60. PubMed ID: 23460233
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety of deferiprone treatment in children from the Mediterranean region with beta-thalassemia major: the DEEP-3 multi-center observational safety study.
Botzenhardt S; Felisi M; Bonifazi D; Del Vecchio GC; Putti MC; Kattamis A; Ceci A; Wong ICK; Neubert A;
Haematologica; 2018 Jan; 103(1):e1-e4. PubMed ID: 29079595
[No Abstract] [Full Text] [Related]
6. Role of vitamin C as an adjuvant therapy to different iron chelators in young β-thalassemia major patients: efficacy and safety in relation to tissue iron overload.
Elalfy MS; Saber MM; Adly AA; Ismail EA; Tarif M; Ibrahim F; Elalfy OM
Eur J Haematol; 2016 Mar; 96(3):318-26. PubMed ID: 26018112
[TBL] [Abstract][Full Text] [Related]
7. Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study.
Hamdy M; El-Beshlawy A; Veríssimo MPA; Kanter J; Inusa B; Williams S; Lee D; Temin NT; Fradette C; Tricta F; Ebeid FSE; Kwiatkowski JL; Elalfy MS
Pediatr Blood Cancer; 2024 Jan; 71(1):e30711. PubMed ID: 37807937
[TBL] [Abstract][Full Text] [Related]
8. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload.
ElAlfy MS; Sari TT; Lee CL; Tricta F; El-Beshlawy A
J Pediatr Hematol Oncol; 2010 Nov; 32(8):601-5. PubMed ID: 20921906
[TBL] [Abstract][Full Text] [Related]
9. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
Marsella M; Borgna-Pignatti C
Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709
[TBL] [Abstract][Full Text] [Related]
10. Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.
Olivieri NF; Sabouhanian A; Gallie BL
PLoS One; 2019; 14(2):e0211942. PubMed ID: 30811439
[TBL] [Abstract][Full Text] [Related]
11. Assessing cardiac and liver iron overload in chronically transfused patients with sickle cell disease.
Badawy SM; Liem RI; Rigsby CK; Labotka RJ; DeFreitas RA; Thompson AA
Br J Haematol; 2016 Nov; 175(4):705-713. PubMed ID: 27507431
[TBL] [Abstract][Full Text] [Related]
12. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients.
Hoffbrand AV; AL-Refaie F; Davis B; Siritanakatkul N; Jackson BF; Cochrane J; Prescott E; Wonke B
Blood; 1998 Jan; 91(1):295-300. PubMed ID: 9414297
[TBL] [Abstract][Full Text] [Related]
13. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
Saliba AN; El Rassi F; Taher AT
Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
Hagag AA; Hamam MA; Taha OA; Hazaa SM
Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
[TBL] [Abstract][Full Text] [Related]
15. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
16. Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network.
Tsouana E; Kaya B; Gadong N; Hemmaway C; Newell H; Simmons A; Whitmarsh S; Telfer P
Eur J Haematol; 2015 Apr; 94(4):336-42. PubMed ID: 25138173
[TBL] [Abstract][Full Text] [Related]
17. Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study.
Kwiatkowski JL; Hamdy M; El-Beshlawy A; Ebeid FSE; Badr M; Alshehri A; Kanter J; Inusa B; Adly AAM; Williams S; Kilinc Y; Lee D; Tricta F; Elalfy MS
Blood Adv; 2022 Feb; 6(4):1243-1254. PubMed ID: 34847228
[TBL] [Abstract][Full Text] [Related]
18. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
[TBL] [Abstract][Full Text] [Related]
19. Hepatic and Cardiac Iron-load in Children on Long-term Chelation with Deferiprone for Thalassemia Major.
Totadri S; Bansal D; Trehan A; Khadwal A; Bhatia A; Sodhi KS; Bhatia P; Jain R; Das R; Khandelwal N
Indian Pediatr; 2018 Jul; 55(7):573-575. PubMed ID: 30129538
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
